Entyvio 300mgEntyvio 300mg
ENTYVIO (vedolizumab), an integrin receptor foe, is an acculturated IgG1 monoclonal counter acting agent created in Chinese hamster ovary cells that ties to the human α4β7 integrin. ENTYVIO has a surmised sub-atomic load of 147 kilodaltons.
Nivolumab (Opdivo®) SubsidizedNivolumab (Opdivo®) Subsidized $2,200 – $26,200
What Is Nivolumab (Opdivo)?
- A checkpoint inhibitor, a type of immunotherapy that helps make cancer cells more vulnerable to attack by your body’s own immune system
- An antibody that promotes the tumor-killing effects of T cells (white blood cells that help your body fight disease)
- It is used to treat advanced melanoma that is unresectable or has spread to organs and other parts of the body. In addition, nivolumab is also used as adjuvant therapy, that is, treatment after complete surgical resection of melanoma to reduce the risk of the melanoma returning. To learn more about the use of nivolumab as adjuvant therapy for melanoma.